The introduction of CAR T-cell therapy has revolutionized the treatment landscape for Acute Lymphoblastic Leukemia (ALL), offering hope to patients with relapsed or refractory forms of the disease. This breakthrough immunotherapy, which involves genetically engineering a patient’s T cells to target and destroy cancer cells, has significantly advanced oncology care.
Comments
0 comment